drugset
drugset / Trial / NCT01985295

Combined Modality Treatment of Sarcomas of the Extremities

NCT01985295 ↗

Phase 1 Completed 12 enrolled The Netherlands Cancer Institute GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

In this study, we aim to define the recommended dose of a VEGFR-TKI (pazopanib) in combination with RT pre-operatively given.

Timeline

Start
2010-06
Primary completion
2014-08
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule 400 mg Oral
Subject Pazopanib Small molecule 600 mg Oral
Subject Pazopanib Small molecule 800 mg Oral

Indications

soft tissue sarcoma